Merck leans on new Keytruda formulation to keep away from patent cliff (NYSE:MRK)
Erik S. Lesser Merck (NYSE:MRK) is unlikely to permit competitors to harm prospects for its blockbuster most cancers remedy Keytruda anytime quickly, with a Reuters report on Friday indicating that the corporate is readying an…